Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$0.45 ▼ -0.04
(-9.07%)
MKT CAP: $47.7M • VOL: 2.84M
52W L $0 52W H $4
ROARABLE / RQD
D- • 43/100
PIOTROSKI
4 / 9
CRBU // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $11.2M | $10.0M | $34.5M |
| YoY Revenue Growth % | +11.7% | -71.0% | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$148.3M | -$166.6M | -$116.1M |
| Operating Margin % | -80.0% | -80.0% | -80.0% |
| Net Income (GAAP) | -$148.1M | -$149.1M | -$102.1M |
| EBITDA (Normalized) | -$147.3M | -$162.7M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$111.0M | -$138.2M | -$93.3M |
| Capital Expenditures (CapEx) | $1.4M | $4.9M | — |
| Free Cash Flow (FCF) | -$112.4M | -$143.1M | -$93.3M |
| FCF Margin % | -80.0% | -80.0% | -80.0% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $12.4M | $16.3M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $122.2M | $253.0M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR CRBU.